Risedronate Sodium Tablet, Delayed Release
Product Images NDC 59762-0407

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 59762-0407). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Following Chemical Structure Of Risedronate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Risedronate Sodium Tablet For Oral Administration Contains The Equivalent Of 35 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Risedronate Sodium 01)

The Following Chemical Structure Of Risedronate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Risedronate Sodium Tablet For Oral Administration Contains The Equivalent Of 35 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Risedronate Sodium 01)
Chemical structure of risedronate sodium showing a pyridine ring attached to a bisphosphonate group with hydroxyl and phosphonate functional groups, along with 2.5 molecules of water of hydration.*
FDA Label Image

Figure 1 (Risedronate Sodium 02)

Figure 1 (Risedronate Sodium 02)
A bar chart titled 'Nonvertebral Osteoporosis-Related Fractures Cumulative Incidence Over 3 Years Combined VERT MN and VERT NA' comparing percent of patients with fractures between Placebo and ACTONEL 5 mg groups across various body parts, including All, Wrist, Humerus, Hip, Pelvis, Leg, and Clavicle.*
FDA Label Image

Principal Display Panelndc 59762-0407-4risedronate Sodiumdelayed-release Tablets35 mg4 Tabletsonce-a-weekrx Only (Risedronate Sodium 03)

Principal Display Panelndc 59762-0407-4risedronate Sodiumdelayed-release Tablets35 mg4 Tabletsonce-a-weekrx Only (Risedronate Sodium 03)
Packaging label for Greenstone brand Risedronate Sodium delayed-release tablets, 35 mg strength. The label indicates a pack of 4 tablets with a once-a-week dosing instruction. The labeler is Mylan Pharmaceuticals, Inc., and the NDC is 59762-0407. The design includes text emphasizing the dosage and product name on a light background with green and yellow highlights.*
FDA Label Image

Risedronate Sodium 04

Risedronate Sodium 04
Packaging label for Risedronate Sodium delayed-release tablets, 35 mg strength, by Mylan Pharmaceuticals, Inc. The label includes the Greenstone brand name, dosage and quantity information (4 tablets), and instructions for opening the child-resistant package. It directs users to read the enclosed Medication Guide and features markings for dosage and product identification.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.